U.S. drugmaker Moderna must decide which country would be first to get an experimental vaccine it is developing for COVID-19, should the treatment prove successful, Lonza Chairman Albert Baehny told CNBC this week. Contract drug manufacturer Lonza, which has a 10-year deal with Moderna to make up to a billion doses annually, is expanding its U.S. production capacity to be able to supply large volumes by December, according to Baehny. The talk of boosting production comes amid intensifying debate over who should get a successful vaccine candidate first, given mass supplies will take time to produce, manufacturing capacity is limited, and the United States has chipped in $500 million in funding for Moderna’s project. Learn More